The high uptake of PSMA-targeting ligands by solid tumors other than prostate carcinomas, based on underlying overexpression of this marker on their neovasculature and the lack thereof on normal vessels as evidenced by histology, renders PSMA a highly interesting target for antiangiogenic therapy. The gene discussed is FOLH1; the disease is prostate carcinoma.